A first-in-class oligonucleotide drug-antidote pair efficiently modulates factor IXa activity in human subjects - A nascent platform for antidote-controlled periprocedural anticoagulation
Publication
, Journal Article
Chan, MY; Cohen, MG; Rusconi, CP; Alexander, JH; Myles, SK; Aberle, LG; Lin, M; Melloni, C; Tonkens, RM; Harrington, RA; Becker, RC
Published in: CIRCULATION
October 16, 2007
Duke Scholars
Published In
CIRCULATION
ISSN
0009-7322
Publication Date
October 16, 2007
Volume
116
Issue
16
Start / End Page
617 / 617
Location
Orlando, FL
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Chan, M. Y., Cohen, M. G., Rusconi, C. P., Alexander, J. H., Myles, S. K., Aberle, L. G., … Becker, R. C. (2007). A first-in-class oligonucleotide drug-antidote pair efficiently modulates factor IXa activity in human subjects - A nascent platform for antidote-controlled periprocedural anticoagulation. CIRCULATION, 116(16), 617–617.
Chan, Mark Y., Mauricio G. Cohen, Christopher P. Rusconi, John H. Alexander, Shelley K. Myles, Laura G. Aberle, Min Lin, et al. “A first-in-class oligonucleotide drug-antidote pair efficiently modulates factor IXa activity in human subjects - A nascent platform for antidote-controlled periprocedural anticoagulation.” CIRCULATION 116, no. 16 (October 16, 2007): 617–617.
Chan MY, Cohen MG, Rusconi CP, Alexander JH, Myles SK, Aberle LG, et al. A first-in-class oligonucleotide drug-antidote pair efficiently modulates factor IXa activity in human subjects - A nascent platform for antidote-controlled periprocedural anticoagulation. CIRCULATION. 2007 Oct 16;116(16):617–617.
Chan, Mark Y., et al. “A first-in-class oligonucleotide drug-antidote pair efficiently modulates factor IXa activity in human subjects - A nascent platform for antidote-controlled periprocedural anticoagulation.” CIRCULATION, vol. 116, no. 16, LIPPINCOTT WILLIAMS & WILKINS, Oct. 2007, pp. 617–617.
Chan MY, Cohen MG, Rusconi CP, Alexander JH, Myles SK, Aberle LG, Lin M, Melloni C, Tonkens RM, Harrington RA, Becker RC. A first-in-class oligonucleotide drug-antidote pair efficiently modulates factor IXa activity in human subjects - A nascent platform for antidote-controlled periprocedural anticoagulation. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2007 Oct 16;116(16):617–617.
Published In
CIRCULATION
ISSN
0009-7322
Publication Date
October 16, 2007
Volume
116
Issue
16
Start / End Page
617 / 617
Location
Orlando, FL
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology